mirikizumab   Click here for help

GtoPdb Ligand ID: 9846

Synonyms: Antibody I [US9023358] | LY-3074828 | LY3074828 | mirikizumab-mrkz | Omvoh®
Approved drug Immunopharmacology Ligand
mirikizumab is an approved drug (Japan, EMA and FDA (2023))
Compound class: Antibody
Comment: Mirikizumab (LY-3074828) is a humanized monoclonal antibody against human IL-23A (IL-23p19) which is designed for the treatment of autoimmune diseases. It is one of the novel agents for immune-mediated inflammatory diseases discussed in Baker et al. (2018) [1]. The peptide sequences of mirikizumab heavy and light chains are 100% matches to sequences 9 and 10 of Antibody I that is claimed in patent US9023358 [2].
1. Baker KF, Isaacs JD. (2018)
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?.
Ann Rheum Dis, 77 (2): 175-187. [PMID:28765121]
2. Beidler CB, Bright SW, Girard DS, Kikly KK. (2015)
Antibodies that bind to IL-23.
Patent number: US9023358B2. Assignee: Eli Lilly and Co Ltd (GB). Priority date: 08/03/2013. Publication date: 05/05/2015.
3. Keam SJ. (2023)
Mirikizumab: First Approval.
Drugs, 83 (11): 1045-1052. [PMID:37389706]
4. Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, Tuttle JL, Klekotka P, Friedrich S, Durante M et al.. (2020)
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
Gastroenterology, 158 (3): 537-549.e10. [PMID:31493397]